Kindai University · Kindai University Hospital · 講師

Research keywordsegfr mutant lung cancer・alk positive nsclc・ctdna profiling・tyrosine kinase resistance・brain metastases・fak inhibitor trials

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• The anti-EGFR monoclonal antibody blocks cisplatin-induced activation of EGFR signaling mediated by HB-EGF
• Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade.
• CLINICAL BENEFIT OF CONTINUED THERAPY WITH CRIZOTINIB BEYOND INITIAL DISEASE PROGRESSION IN ADVANCED ALK POSITIVE NSCLC
• Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic Colorectal Cancer

• 非小細胞肺癌におけるEGFR-TKI耐性克服戦略の最適化に関わる研究

• Official profile